Oncology

Landmark trial shows proton therapy boosts survival and cuts side effects, offering new hope as cancer rates climb in adults under 50.

With Christoph Korpus at the helm, Byondis signals a strategic shift to accelerate its innovative cancer therapies through new partnerships and commercialization.

A new non-invasive therapy using ultrasound to activate a cancer-targeting drug enters a crucial Phase 2b trial, offering new hope for glioblastoma patients.

Satri-cel, the world's first CAR-T therapy for solid tumors, is set to launch in China, offering a powerful new weapon against advanced stomach cancers.

TAE Life Sciences' new therapy combines precision radiation with immunotherapy, showing 100% tumor regression in preclinical studies for hard-to-treat cancers.

Celebrating a decade of challenging norms, AESARA eyes its next chapter in global health, armed with AI, RWE, and a focus on complex diseases.

Blue Faery recognizes two doctors whose groundbreaking research in immunotherapy and targeted drugs has created new standards of care for liver cancer patients.

A new alliance between Daiichi Sankyo and ATLATL aims to leverage a unique 'Super Server' model to fast-track novel therapies from Asia to the world.

Early Phase 3 results show gotistobart dramatically extends survival for lung cancer patients with limited options, heralding a potential new standard of care.

As lung cancer becomes a growing crisis for women, the LCRF gala honors two leaders driving change and rallying support for life-saving research.

The firm adds veteran TD Cowen analyst Boris Peaker to deepen its research in oncology and genetic medicines, signaling a major bet on specialized insight.

A new trial for advanced liver cancer tests visugromab, a drug aiming to overcome immunotherapy resistance and reverse debilitating cancer-related wasting.

A novel interferon-based therapy from ABION shows promise in preclinical studies, overcoming resistance to current cancer drugs and activating the immune system.

With diagnostic sales fueling a diverse therapeutic arsenal, Telix reaffirms blockbuster guidance and advances pivotal trials for prostate, brain, and kidney cancers.

A groundbreaking trial testing if a coffee infused with an ancient herb can slow prostate cancer recurrence is nearing completion, offering hope for a new era.

New York Medicaid now funds a vital therapy to prevent chemo-induced hair loss, breaking down financial barriers for low-income cancer patients.

Boston's Bio-IT World conference shifts from AI theory to execution, showcasing how the life sciences industry is now deploying AI to accelerate new therapies.

With a multi-billion dollar track record of IPOs and acquisitions, the veteran CEO's appointment signals Frazier's focus on navigating complex markets.

New preclinical data for ATNM-400 and Actimab-A shows promise for treating resistant solid tumors and AML, highlighting a new frontier in cancer therapy.

Clinical AI launches MAIA™ on Google Cloud Marketplace, using Gemini AI to solve the patient enrollment crisis that stalls 80% of medical studies.